Prof. Dr. Lieven Annemans
|Learn about the language, key principles and methods of health economic evaluations.|
|Know how to interpret the results of health economic evaluations.|
|Learn to integrate health economic evaluations in product development, pre-marketing and post launch.|
|Gain insight into the perspective of decision makers.|
|Ensure alignment of health economics with marketing strategies.|
|Understand and avoid the pitfalls of health economic evaluations.|
|Gain expert insight and advice from Lieven Annemans who conducted health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas.|
The expert: Our expert-trainer, Prof. Lieven Annemans, not only has a wide international experience in health economic evaluations (over 200 completed projects with over 30 different pharmaceutical or medical device companies) but also built a very strong reputation within the international pharmaco-economic community as a high-impact trainer. Throughout his career, Lieven has worked in pharmaceutical companies, in health care policy environments, in consultancy and in academic positions.
The content: This course not only provides you with an explanation of concepts and methods. More importantly, it discusses the integration of health economic evaluation in clinical development and brand marketing plans (with practical examples), as well as the perspective of the decision maker, including examples of successful applications of health economic evaluations.
As the course title suggests, this course is designed for non-health-economists.
As pharma companies are facing ever-increasing hurdles to optimize market access for their brands, all managers in product development and marketing should attend such course so that they can contribute to a successful integration of health economic evaluations into clinical and brand plans.
Below is a non-exhaustive list of executives who participated in the Health Economics for Non-Health-Economists course:
Sales Manager SEE Abbott Vascular Abbott Croatia testimonial Scientific Affairs Manager Abbott Germany testimonial Business Unit Director AbbVie Czech Republic & Slovakia testimonial Regulatory Affairs Manager Amgen Belgium testimonial Medical and Health Outcome Advisor Baxter The Netherlands testimonial Global Advocacy Manager Bayer Germany testimonial Health Economics Specialist Bayer Turkey testimonial Pricing Manager Bayer Schering Pharma Germany testimonial Global Teamleader, Marketing Pipeline Products Boehringer Ingelheim Germany testimonial Head of RCV - Emerging Market Russia Boehringer Ingelheim Austria testimonial National Market Access Manager, Speciality Medicine Boehringer Ingelheim UK testimonial Pricing Manager Boehringer Ingelheim UK testimonial Regional Operations Manager Boehringer Ingelheim UK testimonial Market Access and Public Affairs Director Bristol-Myers Squibb Portugal testimonial Pricing & Health Economics Manager Bristol-Myers Squibb Romania testimonial Country Manager Celgene Belgium Disease Area Access Lead, Europe BMS UK testimonial Commercial Operations Vice President Daiichi Sankyo Germany Sales & Product Manager Ferring Denmark testimonial Regulatory Affairs & QA Mgr Genzyme Belgium testimonial Commercial Excellence Manager Guerbet France testimonial Executive Director Market Access Grünenthal Germany Health Economics & Outcomes Research Coordinator GSK Turkiye Business Development Scientist GW Pharmaceuticals UK testimonial Senior Director Janssen Belgium testimonial VP Licensing & New Business Development EMEA Janssen Pharmaceutica Belgium Director Government Affairs EMEA J&J Belgium testimonial Market Access Manager LEO Pharma Portugal testimonial Project Manager LEO Pharma Denmark testimonial Global Project Leader Merck Serono Switzerland testimonial Health Economics Manager MSD The Netherlands Clinical Trial Officer Mundipharma The Netherlands Medical Officer Mundipharma Belgium testimonial Business Intelligence Manager Novartis Belgium testimonial Head BF IDTI & Ophthalmics Novartis The Netherlands testimonial Global Associate Market Access Director Novartis Switzerland testimonial Market Access Head Novartis Russia testimonial Medical Scientific Liaison Novartis The Netherlands testimonial Market Access Business Analyst Novo Nordisk Iran testimonial Sales Effectiveness Manager - International Operations Novo Nordisk Switzerland testimonial Health Economics & Market Access Manager Nutricia The Netherlands testimonial Development Leader Orion Pharma Finland testimonial European Director Pfizer UK Senior Scientific Adviser Pfizer UK testimonial Program Manager Roche Diagnostics Switzerland testimonial In-Market Pricing Manager Roche Switzerland testimonial Senior Director, Value & Access Leader Sanofi France testimonial Strategic Planning & Market Access Manager Sanofi Romania testimonial Sales Force Excellence & Business Process Manager Sanofi-aventis Denmark Commercial Director Sanofi-aventis Ukraine testimonial Medical Affairs Manager Sanofi Pasteur MSD The Netherlands testimonial Senior Director, Global Medical Affairs Sanofi Pasteur France testimonial Head Anesthesia & Analgesia - Global Clinical Research Schering Plough The Netherlands testimonial Market Access Officer Servier Romania testimonial Associate Director Global Market Research Shire Belgium testimonial Medical Director Shire France testimonial Medical Manager Shire France testimonial Industrial Pharmacist SMB Belgium testimonial Head of Global Regulatory Solvay Germany European Marketing Manager Takeda UK testimonial European Marketing Manager, Established Brands Takeda UK testimonial Medical Scientist The Medicines Company Italy testimonial Medical Writer Trial Form Support Denmark testimonial Pharmacovigilance & Clinical Trial Manager Vianex Greece testimonial Medical Scientific Liaison Officer Vifor Pharma The Netherlands testimonial
The course starts on day 1 at 09:30h with a welcome coffee and ends on day 2 at 16:30h.
Welcome & General Introduction
Health Economic Evaluations: Why and How
- Why health economic evaluations receive increasing attention
- Key definitions & terminology: talking the same language
- From value proposition to cost-effectiveness
- Key methods of health economic evaluations
Exercises on QALYs
Health Economic Modelling – Commonly Used Models
- Back of the envelope models
- Simple decision trees (+ real examples)
- Markov models (+ real examples)
Issues in Analysing Costs and Savings
- The perspective of the study (e.g. building in absenteeism in the value message?)
- The study setting: hospital-based drugs and ambulatory drugs require different approaches!
- How to deal with current benefits versus benefits in the far future?
- Budget impact implications: state-of-the-art
Exercise on budget impact
Guidelines for the Conduct and Reporting of Health Economic Evaluation
- What distinguishes a good from a bad health economic evaluation?
- What can one do to increase the credibility of health economic messages in the value message?
- A 10-item checklist for a good health economic paper
BREAK OUT SESSION: how to distinguish a good health economic paper from a poor quality paper.
Prospective Health Economic Evaluations
- Aligning the collection of health economic data and clinical data
- Conflicts between the clinical and the health economic perspective
- Practical steps for prospective health economic studies
Use of Health Economic Evaluations in Healthcare Decision Making
- The large differences in payer expectations
- Communication challenge: from very simple messages to high tech requirements
- Pitfalls of health economic evaluations: why some messages fail to have an impact, and how to solve this
Health Economic Evaluation in a Pharmaceutical Drug's Life Cycle
- Role of early economic models
- Organisation and process within HQ and affiliates
- The cost-effectiveness of cost-effectiveness studies
- How to prepare for a second assessment
BREAK OUT SESSION: Developing together a health economic strategy
Final Discussion and Close
Prof. Lieven Annemans is very experienced in leading interactive sessions and will actively engage participants in discussions. In addition, two exercises will be used to help bringing theory into practice.
Lieven Annemans is a Full Professor of Health Economics at Ghent University and Brussels University. He is Past-President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, member of the Flemish Council of Health and Wellbeing (advising the Minister of Health), and external expert to the Belgian HTA body “KCE”. He has experience in health economic evaluations of medicines, medical devices and preventive health actions in various medical areas, and conducted studies in over 20 countries. He is currently also active as an independent consultant in health economics and prior to his professorship he has also worked in the pharma industry.
His main interests are epidemiological models, early health technology assessment (HTA), retrospective/ prospective health economic evaluations, and physician payment systems. He has published over 170 papers in peer-reviewed journals, presented over 300 posters/papers at conferences and has given over 500 lectures and trainings on health economic evaluation. He is the author of the book “Health economics for non-economists: an introduction to the principles, methods and pitfalls of health economic evaluations” (email@example.com).
22-23 May 2014, Zurich
This course takes place at the Hilton Zurich Airport Hotel which is located just five minutes from Zurich Kloten Airport with the complimentary shuttle. Zurich’s vibrant city center is located only a fifteen minutes drive away.
Hilton Zurich Airport Hotel
Tel: +41 44 828 50 50
Fax: +41 44 828 51 51
We have secured preferential room rates at this hotel for our delegates. Registering three weeks or more prior to the course will secure your room at a preferential rate. Upon your registration, C.E.L.forpharma will send you a Hotel Accommodation Sheet to complete and send back.
Do not hesitate to contact Marie Stricklesse, Senior Programme Coordinator, if you need assistance in this matter. (firstname.lastname@example.org; tel +32(0)27090143)
25-26 September 2014, Brussels
2-3 December 2014, Brussels
These courses take place at the Sheraton Airport Hotel & Conference Center which is situated opposite Brussels National Airport, literally at 2 minutes' walking distance from the arrival hall.
Sheraton Brussels Airport Hotel
Brussels National Airport
Tel: +32 27 10 80 00
Fax: +32 27 10 80 80
We have secured preferential room rates at this four-star hotel for our delegates. Registering three weeks or more prior to the course will secure your room at a preferential rate. Upon your registration, C.E.L.forpharma will send you a Sheraton Brussels Airport Hotel Accommodation Sheet to complete and send back.
Do not hesitate to contact Marie Stricklesse, Senior Programme Coordinator, if you need assistance in this matter. (email@example.com; tel +32(0)27090143)
22-23 May. 2014 Course, Zurich (HEC-17) Price(*) Registration after 4 April 2014 €3.370
25-26 Sep. 2014 Course, Brussels (HEC-18) Price(*) Registration before 8 August 2014 €2.970 Registration after 8 August 2014 €3.370
2-3 Dec. 2014 Course, Brussels (HEC-19) Price(*) Registration before 17 October 2014 €2.970 Registration after 17 October 2014 €3.370* (VAT excl.)
To register, please go to our online registration form.
"Lieven has a lot of expertise and is a highly knowledgeable trainer with very good presentation skills. This course was very fruitfull. Highly recommended!"
Alireza Firooz, Market Access Business Analyst, Novo Nordisk - Iran (March 2014)
"The course was very useful, well-structured and to the point. I will certainly advice it to my other colleagues."
Morteza Yazdani, Global Associate Market Access Director, Novartis – Switzerland (January 2014)
"Excellent course! Pitched right and paced right. I enjoyed Lieven's acknowledged suggestions and input."
Gavin Rimmer, National Market Access Manager, Speciality Medicine, Boehringer Ingelheim – UK (January 2014)
"I enjoyed the training very much, very useful!!"
Thierry Barten, Medical Scientific Liaison Officer, Vifor Pharma – The Netherlands (January 2014)
"Very good course. Very good speaker with a good balance of interaction (discussion and exercises)."
Lotte Groth, Project Manager, LEO Pharma – Denmark (January 2014)
"Lieven Annemans is a very engaging coach and is able to present very difficult things in a very simple and understandable way. Professional and interesting course which provides in 2 days detailed understanding of HE."
Olga Shirokova, Market Access Head, Novartis – Russia (December 2013)
"C.E.L.forpharma is a very good organization, extremely helpful. Lieven has very good communication and listening skills. He masters his topic and could clearly explain it. This course could be a starting point to reconsider my orientation in the pharma industry. Thank you!!"
Sabrina Paillé, Medical Manager, Shire – France (December 2013)
"Programme very well adapted for non-health-economists. Prof. Lieven Annemans is fantastic and passioned."
Karim Keddad, Medical Director, Shire – France (December 2013)
"A great healtheconomics course that was clearly delivered and that will genuinely help my day-to-day work!"
Neil Beasley, Global Advocacy Manager, Bayer – Germany (December 2013)
"Great hands-on training course with a very knowledgeable speaker."
Bart De Pot, Business Intelligence Manager, Novartis – Belgium (December 2013)
“Lieven Annemans has a lot of expertise and enthusiastically mixes theory, practice and examples. This course was very fruitful!”
Christophe Charrier, Commercial Excellence Manager, Guerbet – France (September 2013)
"Very useful course for market access specialists who need to get a better understanding of pharmaco-economic concepts and their limitations!"
Eddine Maiza, Senior Director, Sanofi – France (September 2013)
"Very comprehensive course given in an easy digestible manner!"
Caroline Hoefkens, Regulatory Affairs Manager, Amgen – Belgium (September 2013)
"Lieven is making this "hard to understand" topic extremely interesting and in a simple language. Content was well organised and informative. I liked the structure of lectures and I am very satisfied with the level of knowledge transferred."
Hrvoje Remenar, Sales Manager SEE Abbott Vascular, Abbott - Croatia (May 2013)
"True expert making a potentially dreary topic both interesting and easy to understand."
James Brodie, Business Development Scientist, GW Pharmaceuticals - UK (May 2013)
"For non-health-economists, Lieven's training covers different aspects of HE at the right breadth and depth. With his entertaining presentation style he manages to make a rather dry topic very exciting. Thanks, I learned a lot!"
Katrin Hoffmann, Associate Director Global Market Research, Shire - Belgium (May 2013)
"It was an excellent course, very well organized and Prof. Dr. Lieven is by far the best teacher ever! Highly experienced, but truly accessible! I really enjoyed the course, it was very useful!"
Rita Marques, Market Access Manager, LEO Pharma – Portugal (February 2013)
"Just the right balance of theory and real-life examples to help non-health-economists ask the right questions."
Derek Brown, Global Teamleader, Marketing Pipeline Products, Boehringer Ingelheim – Germany (February 2013)
"Very good course done by a true expert in the field! Lieven is able to give a business-oriented overview of the pharmaco-economics field and challenges in a way that is understandable to non-specialists."
Eric Desauziers, Senior Director, Global Medical Affairs, Sanofi Pasteur - France (February 2013)
"A very clear introduction to health economic evaluations given by a charismatic speaker. Top!"
Emilie Beghin, Regulatory Affairs & QA Mgr, Genzyme - Belgium (February 2013)
"Very interesting course, presented in an animated way, with lots of items covered in a short time frame."
Elke Vandeputte, Medical Officer, Mundipharma - Belgium (February 2013)
"I have finally got a systematic and complete overview of HE."
Bibiana Soltysova, Business Unit Director, AbbVie, Czech Republic & Slovakia (February 2013)
"An excellent two days which delivered on its objectives! An exhaustive insight into HE, tailored appropriately to improve understanding."
Neil Edwards, Regional Operations Manager, Boehringer Ingelheim – UK (December 2012)
"Lieven is a nice and funny presenter. He appreciates different backgrounds and respects opinions. He makes bridges and is able to give practical tips and tricks."
Jolanda Koenders, Medical Scientific Liaison, Novartis – The Netherlands (December 2012)
"Health economics concepts presented and discussed by Lieven are even more exciting! Very refreshing and actual course."
Helena Freitas, Market Access and Public Affairs Director, Bristol-Myers Squibb – Portugal (December 2012)
"Lieven was a very engaging and clear presenter and the two days went very well. Marie also did a fantastic job in keeping the training on track over the 2 days!!"
Debo Aremu, Pricing Manager, Boehringer Ingelheim – UK (December 2012)
"One of the most explicit and comprehensive courses in Health Economics on the market."
Dorian Costescu, Market Access Officer, Servier – Romania (September 2012)
"First class from the start to the very last minute. I will recommend to all people who engage with payers."
Jamie Rice, Regional Operations Manager, Boehringer Ingelheim – UK (September 2012)
"Lieven Annemans is a true expert and is able to explain the materials / themes extremely well. What I especially appreciate is that theories are always accompanied with real life examples. Lieven understands and knows the pharma industry very well."
Saskia De Haes, Senior Director, Janssen – Belgium (September 2012)
"I would recommend this course especially to my colleagues from the medical department so that they would understand the importance of clear end points for HE studies."
Burak Marmarali, Health Economics Specialist, Bayer – Turkey (June 2012)
"This course opened my eyes to the basics of health economics in a fun and educational way! Very valuable and interesting!"
Anna Trisia Beby, Medical and Health Outcome Advisor, Baxter – The Netherlands (June 2012)
"Lieven Annemans is a great expert, with humor, open to all questions and who explained the basic concepts of health economics very clearly!"
Maryvonnic Abeels, Industrial Pharmacist, SMB – Belgium (June 2012)
"Very valuable course to acquire quickly arguments to bring more early HTA into development."
Isabelle Lugan, Global Project Leader, Merck Serono – Switzerland (June 2012)
"Very inspiring speaker. Lieven explains the topic thoroughly and in a 'Layman' language."
Kati Kaijasilta, Development Leader, Orion Pharma – Finland (March 2012)
"Excellent overview for non-health-economists. Great teacher!"
Zenia Storling, Medical Writer, Trial Form Support – Denmark (March 2012)
"This course is highly recommended to all the persons involved in every development stage of a product and all the persons in direct negotiations with the payors."
Nadia Gorduza, Strategic Planning & Market Access Manager, Sanofi - Romania (December 2011)
“Lieven leads the group expertly, building up their knowledge, taking them on a journey, testing and challenging at appropriate times through questions and exercises. Thank you Lieven!”
Avi Leaf, European Marketing Manager, Takeda - UK (November 2011)
“A great introduction to the dark art of health economics.”
Stephen Hogan, Director Government Affairs EMEA, J&J – Belgium (November 2011)
“Appropriate time spent on each topic with international issues as well as individual country issues covered. Perfect level for non-health economist pharma employees.”
Trine Ann Behnk, Sales & Product Manager, Ferring - Denmark (November 2011)
“Very helpful training! Very well delivered!”
Diana Omer, Pricing & Health Economics Manager, Bristol-Myers Squibb - Romania (November 2011)
“This was a highly interesting and engaging course on health economics. The only thing which would have added value would have been time to network and do exercises to understand the implementation of the theory. Great. Loved it.”
Julie Gaughan, Business Partnership Team Manager, Boehringer Ingelheim - UK (November 2011)
“Clear content, well organized, useful discussions.”
Achilleas Kalogirou, Pharmacovigilance & Clinical Trial Manager, Vianex – Greece (November 2011)
"Very good course to learn efficiently about principles of health economics, applications and advantages, but also about limitations in development submission and reimbursement."
Lieselotte Lennartz, Scientific Affairs Manager, Abbott – Germany (May 2011)
"Excellent course, very well delivered - I have learnt a lot. Thank you."
David Maddocks, Disease Area Access Lead, Europe, Bristol-Myers Squibb – UK (May 2011)
"Very well organised and friendly atmosphere. Lieven is a very experienced teacher but also, despite his wealth of knowledge, able to break down the complex theory in clear parts!"
John Rietveld, Head BF IDTI & Ophthalmics, Novartis - The Netherlands (May 2011)
"Invaluable course for any European marketer who needs to develop his understanding of the complex world of health economics. The course leader breaks through the jargon and brings the concepts to life in a relevant and memorable way."
Lisa Williams, European Marketing Manager, Established Brands, Takeda - UK
"I very much appreciated this valuable and practical health economics course, focused on real life cases/examples."
Peter Markotan, Head of RCV - Emerging Market Russia, Boehringer Ingelheim – Austria
"Lieven Annemans is very good in presenting the materials. He is an expert in the field with a lot of practical experience. The group is really good, there are lots of interesting exchanges, and the organisation of the event is on top level. Thank you!"
Oksana Vasiutynska, Commercial Director, Sanofi-aventis – Ukraine
“Lieven has the unique talent and ability to easily break down highly complex subjects and equip the audience with real and tangible tools. He also provides an understanding of the health economics arena. My only regret is not having attended this workshop earlier, as we all need this set of skills to work within the ever changing pharma environment. Well done, this was time well spent.”
Colin Hurworth, Sales Effectiveness Manager - International Operations, Novo Nordisk - Switzerland
“Adequate content, hands-on and up to date. Just right.”
Frank Junker, Program Manager, Roche Diagnostics - Switzerland
“Prof. Dr. Lieven Annemans is great! Enthusiastic and very knowledgeable.”
Gerben Hagenaars, Manager Healthcare Policy, Sanofi-aventis – The Netherlands
“A very useful course making a difficult subject very understandable. Pleasant atmosphere and good presentation skills with a sense of humor. I would advise this to anyone who needs more understanding of the subject!”
Bas Slierendregt, Medical Affairs Manager, Sanofi Pasteur MSD - The Netherlands
“Excellent faculty (Prof. Annemans) and good setting (small group of professionals), thus providing true value. Good mix of theory and practical applications”
Daniel Zollinger, Head Anesthesia & Analgesia - Global Clinical Research, Schering-Plough - The Netherlands
“The health economics workshop was a great introduction to this important area of market access. Now I have the confidence to integrate health economics in the product life cycle plan.”
Manjit Affley, Senior Scientific Adviser, Pfizer – UK
“Great, Lieven, well done! You are a very good communicator with a deep knowledge of the HECON.”
Bruno Bolognese, Medical Scientist, The Medicines Company – Italy
“My investment into the course of Lieven Annemans was cost-effective as the gain of quality is guaranteed in all aspects, in both theoretical and practical insights.”
Zuzana Melekova, In-Market Pricing Manager, Roche – Switzerland
“Great course with a lot of information and clear explanation in every aspect. Every question gets a clear and useful answer. In addition, you get a lot of information in the form of ppt slides that you can use to inform your own colleagues.“
Karen Freyer, Health Economics & Market Access Manager, Nutricia – The Netherlands
“Having a “pricing background” I am so pleased I learned the basics of HE, which is what I need to have a common ground for talking in the same “language” with my HE colleagues. Thanks for this comprehensive, intense training.”
Constanze Trautschold, Pricing Manager, Bayer Schering Pharma – Germany